Morgan Stanley
CVKD icon

Morgan Stanley’s Cadrenal Therapeutics CVKD Stock Holding History

Morgan Stanley’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36K Buy
706
+606
+606% +$2.88K ﹤0.01% 7374
2026
Q1 		$512 Sell
100
-980
-91% -$6.87K ﹤0.01% 7612
2025
Q4 		$7.32K Buy
1,080
+200
+23% +$2.26K ﹤0.01% 6963
2025
Q3 		$12.2K Buy
880
+450
+105% +$5.57K ﹤0.01% 6845
2025
Q2 		$5.18K Sell
430
-700
-62% -$10.4K ﹤0.01% 7024
2025
Q1 		$19.9K Sell
1,130
-16
-1% -$294 ﹤0.01% 6572
2024
Q4 		$16.6K Buy
+1,146
New +$16.6K ﹤0.01% 6628

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Q1WB
Quest 10 Wealth Builders Fuquay-Varina, Virginia $129M AUM 22.73% 1-Year Est. Return

Morgan Stanley's CVKD Position: Q2 2026 in Review

Morgan Stanley increased its Cadrenal Therapeutics (CVKD) stake by 606% in Q2 2026, buying an estimated $2.88K and bringing the position to 706 shares worth $2.36K. The position accounts for ﹤0.01% of the portfolio, ranked #7374.

Morgan Stanley first reported a position in CVKD in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.9K in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Morgan Stanley held 706 shares of Cadrenal Therapeutics worth $2.36K as of Q2 2026.
  • Morgan Stanley bought 606 Cadrenal Therapeutics shares in Q2 2026, an estimated $2.88K.
  • Cadrenal Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7374 holding.
  • Morgan Stanley first reported a position in Cadrenal Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Cadrenal Therapeutics position peaked at $19.9K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.